Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Depression in schizophrenia may be partially responsible for the increased suicide rate in schizophrenic patients, which is more than 20 times higher than that found in the general population. Affective disorders in patients with schizophrenia are associated with a poor outcome, an increased risk of relapse, and a high rate of suicide. There is evidence that atypical antipsychotics may contribute to a reduction in suicidality, and although the new drugs are marketed for the treatment of schizophrenia, their novel psychopharmacologic effects suggest the possibility of other therapeutic applications. Recent studies of the efficacy of the novel antipsychotics found that these agents may produce an antidepressant effect in schizophrenia and may be used as either an adjunctive medication or an alternative to mood stabilizers in patients with affective disorders.

Original languageEnglish (US)
Pages (from-to)41-45
Number of pages5
JournalJournal of Clinical Psychiatry
Volume59
Issue numberSUPPL. 12
StatePublished - Oct 5 1998

Fingerprint

Mood Disorders
Antipsychotic Agents
Schizophrenia
Depression
Suicide
Therapeutics
Antidepressive Agents
Recurrence
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

@article{650f2451e49b40bb8d5183891604e49e,
title = "Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders",
abstract = "Depression in schizophrenia may be partially responsible for the increased suicide rate in schizophrenic patients, which is more than 20 times higher than that found in the general population. Affective disorders in patients with schizophrenia are associated with a poor outcome, an increased risk of relapse, and a high rate of suicide. There is evidence that atypical antipsychotics may contribute to a reduction in suicidality, and although the new drugs are marketed for the treatment of schizophrenia, their novel psychopharmacologic effects suggest the possibility of other therapeutic applications. Recent studies of the efficacy of the novel antipsychotics found that these agents may produce an antidepressant effect in schizophrenia and may be used as either an adjunctive medication or an alternative to mood stabilizers in patients with affective disorders.",
author = "Meltzer, {Herbert Y.}",
year = "1998",
month = "10",
day = "5",
language = "English (US)",
volume = "59",
pages = "41--45",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 12",

}

Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. / Meltzer, Herbert Y.

In: Journal of Clinical Psychiatry, Vol. 59, No. SUPPL. 12, 05.10.1998, p. 41-45.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders

AU - Meltzer, Herbert Y.

PY - 1998/10/5

Y1 - 1998/10/5

N2 - Depression in schizophrenia may be partially responsible for the increased suicide rate in schizophrenic patients, which is more than 20 times higher than that found in the general population. Affective disorders in patients with schizophrenia are associated with a poor outcome, an increased risk of relapse, and a high rate of suicide. There is evidence that atypical antipsychotics may contribute to a reduction in suicidality, and although the new drugs are marketed for the treatment of schizophrenia, their novel psychopharmacologic effects suggest the possibility of other therapeutic applications. Recent studies of the efficacy of the novel antipsychotics found that these agents may produce an antidepressant effect in schizophrenia and may be used as either an adjunctive medication or an alternative to mood stabilizers in patients with affective disorders.

AB - Depression in schizophrenia may be partially responsible for the increased suicide rate in schizophrenic patients, which is more than 20 times higher than that found in the general population. Affective disorders in patients with schizophrenia are associated with a poor outcome, an increased risk of relapse, and a high rate of suicide. There is evidence that atypical antipsychotics may contribute to a reduction in suicidality, and although the new drugs are marketed for the treatment of schizophrenia, their novel psychopharmacologic effects suggest the possibility of other therapeutic applications. Recent studies of the efficacy of the novel antipsychotics found that these agents may produce an antidepressant effect in schizophrenia and may be used as either an adjunctive medication or an alternative to mood stabilizers in patients with affective disorders.

UR - http://www.scopus.com/inward/record.url?scp=0031686985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031686985&partnerID=8YFLogxK

M3 - Review article

C2 - 9766619

AN - SCOPUS:0031686985

VL - 59

SP - 41

EP - 45

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 12

ER -